| Study Title | AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy |
|---|---|
| Protocol ID | AALL1732 |
| Disease (Sub Disease) | B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia |
| Diagnosis Stage | New Diagnosis |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03959085 |
| Trial Status | Open |
| Trial Open Date | 28/10/2019 |
| Sites | John Hunter Children's Hospital / Monash Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Women's & Children's Hospital / The Royal Children's Hospital/ Christchurch Hospital, NZ/ Starship Hospital, NZ |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 1 Year to 24 Years |
| International registry ID's | NCT03959085 |